AI Proteins is a Boston-based biotechnology company pioneering de novo miniproteins as a new class of medicines. Unlike traditional antibody or small-molecule approaches, the company designs miniproteins entirely from first principles using AI, allowing precise control over how a molecule binds and behaves against a target.
The company's platform combines AI-driven protein design with high-throughput experimental validation, enabling rapid iteration across large numbers of candidate molecules. Miniproteins offer potential advantages in stability, manufacturability, and tunable properties relative to larger biologics.
In November 2025, AI Proteins closed a $41.5M Series A led by Mission BioCapital and Santé Ventures, with participation from Lightchain Capital, Cobro Ventures, and others. This followed an $18.2M seed round in 2022. The capital supports advancement of its de novo miniprotein therapeutic pipeline.
AI Proteins was founded in 2021 by Chris Bahl, Marc Cohen, and Carl Novina, drawing on advances in computational protein design. The company sits at the intersection of generative biology and drug development, aiming to turn programmable proteins into validated therapeutics.